Couturier J et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000;13(11):1238-43. Abstract.

Field AS et al. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology 2001;33(3):278-82. Abstract.

Larsimont D et al. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: Implications for daily laboratory practice. Anticancer Res 2002;22(4):2485-90. Abstract.

McCormick SR et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: Comparison of HercepTest^TM and PathVysion commercial assays. Am J Clin Pathol 2002;117(6):935-43. Abstract.

Ridolfi RL et al. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000;13(8):866-73. Abstract.

Tubbs RR et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19(10):2714-21. Abstract.

Bartlett J et al. The clinical evaluation of HER-2 status: Which test to use? J Pathol 2003;199(4):411-7. Abstract.

Cianciulli AM et al. Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. Cancer Genet Cytogenet 2002;133(1):66-71. Abstract.

Dowsett M et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199(4):418-23. Abstract.

Gupta D et al. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003;119(3):381-7. Abstract.

Konigshoff M et al. HER-2/neu gene copy number quantified by real-time PCR: Comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem 2003;49(2):219-29. Abstract.

Press MF et al. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20(14):3095-105. Abstract.

Thomson TA et al. HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001;14(11):1079-86. Abstract.

Yaziji H et al. Testing for HER-2/neu in breast cancer: Is fluorescence in situ hybridization superior in predicting outcome? Adv Anat Pathol 2002;9(6):338-44. Abstract.